Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of novel, premium-priced drugs and the progression of Wyeth's Mylotarg (gemtuzumab ozogamicin) to a first-line therapy will more than double the market to treat acute myeloid leukemia by 2015.
The new Pharmacor report Acute Myeloid Leukemia finds that increased use of Mylotarg and the launches of Genzyme/Bioenvision's Clolar/Evoltra (clofarabine), Vion's Cloretazine (VNP-40101M), and SuperGen/MGI Pharma's Dacogen (decitabine) will increase sales from approximately $160 million in 2005 to nearly $340 million in 2015. The report also finds that the current market leader in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom -- Pfizer's Idamycin/Zavedos -- will lose significant sales during the 2005-2015 study period as Mylotarg and Clolar become the market leaders.
"Mylotarg and Clolar will garner shares of 19% and 17%, respectively, in 2015 for the treatment of acute myeloid leukemia, and their premium pricing will be a key factor in boosting the overall value of the market," said Jeremy Goldman, M.D., analyst at Decision Resources. "Additionally, physicians indicate that the future treatment of acute myeloid leukemia will include novel targeted agents that are currently in early-stage development, such as FLT3 inhibitors, including Novartis's midostaurin."
About Acute Myeloid Leukemia
Acute myeloid leukemia is an overproduction of immature myeloid white blood cells in the bone marrow, blood, or other tissues. Only 20-30% of patients experience long-term disease-free survival, and most patients die of the disease. In 2005, an estimated 50,000 people were suffering from acute myeloid leukemia in the United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/